Shionogi & Co., Ltd. (SGIOF)

F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in Medical Mycology (TIMM) 2023 Demonstrating Positive Therapeutic Responses in Patients with Invasive Fungal Infections Treated with Oral Olorofim

An overall success rate of 28.7% was seen at day 42, the primary endpoint, and 27.2% at day 84, as determined by a data review committee (DRC) using the EORTC-MSG criteriaThe success rate rose to 75.2% at day 42 and 63.4% at day 84 when stable disease was counted as successAll-cause mortality (ACM) at day 42 and day 84 was 11.4% and 15.8%, respectively MANCHESTER, United Kingdom and OSAKA, Japan, Oct. 21, 2023 (GLOBE NEWSWIRE) -- F2G Ltd. and Shionogi & Co., Ltd., today announced full results fr